Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis
Preprint
Abstract
Background: Evidence on menopausal hormone replacement therapy (HRT) and disability progression in women with multiple sclerosis (MS) is limited, particularly in the era of high-efficacy disease-modifying therapy. We estimated the association between systemic HRT and sustained disability progression and recurring relapses in a contemporary national cohort. Methods: In a nationwide Swedish registry-based cohort, we followed women with MS aged 40 to 60 years entering from 2006 through 2024, with follow-up through 2025, under a new-user design. Systemic HRT was modeled as time-varying current use and quarterly oral-equivalent dose categories. Outcomes were sustained Expanded Disability Status Scale (EDSS) 4.0, sustained EDSS 6.0, and recurring relapses. Cox models adjusted for baseline covariates and time-varying age and disease-modifying therapy (DMT) class. Results: Among 7,623 women, 1,192 (15.6%) initiated HRT. Current HRT use was associated with a lower hazard of sustained EDSS 4.0 (adjusted hazard ratio [aHR] 0.70, 95% confidence interval [CI] 0.51 to 0.96) but not sustained EDSS 6.0 (aHR 0.80, 95% CI 0.55 to 1.16) or recurring relapses (aHR 1.00, 95% CI 0.74 to 1.36). Dose categories showed no consistent gradient. Raising the cohort-entry age floor to 50 years gave a consistent EDSS 4.0 estimate (aHR 0.62, 95% CI 0.40 to 0.95). Conclusions: HRT was not associated with increased relapse risk or severe disability progression. The lower hazard of sustained EDSS 4.0 was not mirrored at EDSS 6.0 and showed no dose gradient. Given menopausal status was unmeasured, replication in cohorts with verified menopausal status is required for clear clinical interpretation.Keywords
Funding Information
- Swedish Research Council (2023-02567)
This publication has 29 references indexed in Scilit:
- The association of menopausal hormone levels with progression-related biomarkers in multiple sclerosisMultiple Sclerosis and Related Disorders, 2024
- Hormonal Therapies in Multiple Sclerosis: a Review of Clinical DataCurrent Neurology and Neuroscience Reports, 2023
- Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple SclerosisJAMA Neurology, 2021
- Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trialThe Lancet Neurology, 2016
- Revisiting the roles of progesterone and allopregnanolone in the nervous system: Resurgence of the progesterone receptorsProgress in Neurobiology, 2014
- Multiple sclerosis: Neuroprotective alliance of estrogen–progesterone and genderFrontiers in Neuroendocrinology, 2012
- Estrogen treatment in multiple sclerosisJournal of the Neurological Sciences, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Rate of Pregnancy-Related Relapse in Multiple SclerosisNew England Journal of Medicine, 1998
- A non‐parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non‐responder biasStatistics in Medicine, 1984